Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00043914 |
This study includes patients 16 years of age or older with a confident diagnosis of epilepsy who are currently treated with an antiepileptic drug (AED) monotherapy but require a change in therapy due to inadequate seizure control and/or unacceptable side effects.
Condition | Intervention | Phase |
---|---|---|
Epilepsy |
Drug: lamotrigine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients With Epilepsy |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Study Director: | GSK Clinical Trial, MD | GlaxoSmithKline |
Study ID Numbers: | LAM40013 |
Study First Received: | August 14, 2002 |
Last Updated: | March 7, 2006 |
ClinicalTrials.gov Identifier: | NCT00043914 |
Health Authority: | United States: Food and Drug Administration |
epilepsy monotherapy conversion |
Calcium, Dietary Epilepsy Lamotrigine |
Central Nervous System Diseases Brain Diseases Valproic Acid |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Therapeutic Uses Nervous System Diseases Calcium Channel Blockers |
Cardiovascular Agents Central Nervous System Agents Anticonvulsants Pharmacologic Actions |